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Short report
FMR3 is a novel gene associated with FRAXE




We have identified a novel gene, FMR3,
originating from the FRAXE CpG island.
The FMR3 gene is transcribed from the
opposite strand to the FMR2 gene. Analo-
gous to the silencing of the FMR1 and
FMR2 genes, FMR3 transcription is extin-
guished by FRAXE full mutation. Al-
though the role of FMR3 in FRAXE
associated mild to borderline mental re-
tardation is not yet clear, lack of expres-
sion of FMR3 in FRAXE full mutation
males means that the FMR3 gene is
potentially involved.
(J Med Genet 2000;37:782–784)
Keywords: FMR2; FMR3; FRAXE; mental retardation
FRAXE associated mental retardation
(FRAXE MR1) is the most prevalent form of
non-specific X linked mental retardation
(MRX) aVecting at least 1 in 23 423 males.2–4
The molecular basis for this disorder has been
identified as the absence5 6 or truncation5 of the
FMR2 protein. This is a consequence of either
methylation of the FRAXE CpG island in sub-
jects with the full mutation (>200 CCG
copies) and consequent transcription silencing
of the FMR2 gene,7 or deletion within the
FMR2 gene.5 8 No FMR2 specific point muta-
tions have been reported so far. The 5' end of
the FMR2 gene lies within the FRAXE CpG
island. Although the transcription of the
FRAXE CCG repeat as part of the FMR2 gene
has been suggested,9 there are currently no
experimental data supporting this.
In silico search for FMR3 was prompted by
identification of a mildly mentally retarded
patient with a submicroscopic deletion of
FMR2 intron 3 sequences,8 which has no
apparent eVect on expression of the FMR2
gene (unpublished data). Database searches
(EST division of GenBank) with genomic
sequence around FRAXE identified a single
EST, AI470948. The sequence of this EST
starts from the FRAXE NotI site, only 3 bp
from the putative FMR2 transcription start
site9 and only 23 bp proximal to the FRAXE
CCG repeat (fig 1A). Comparison of EST
AI470948 and FRAXE genomic sequence
(AC002368) identified two exons separated by
a 2.1 kb intron (fig 1B). RT-PCR analysis
across this intron showed that this EST
originated from a new gene, FMR3, tran-
scribed in the opposite orientation to FMR2.
Transcription of FMR3 from the opposite
strand to that of the FMR2 gene was also con-
firmed using gene specific primer synthesis of
cDNA followed by PCR (results not shown).
Figure 1 Diagram of FRAXE CpG island and FMR2 and FMR3 genes. (A) Sequence
around FRAXE CCG repeat (boxed) indicating transcription start of FMR3 and FMR2
genes. Original primers 603 and 598 used for FRAXE CCG PCR1 are shown by arrows.
Dotted lines indicate deletions within the FRAXE CpG island found either in females with
POF11 (rows 1-4) or a male with mental retardation10 (row 5). Upper case letters indicate
exons, lower case letters indicate intronic sequences. (B) Position and orientation of
transcription of the FMR3 gene in respect to the FRAXE CCG repeat and the FMR2 gene
is shown (not drawn to scale).
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Northern blot analysis with the 1.2 kb insert of
the EST AI470948 identified ∼3.8 kb low
abundance transcript expressed in adult brain
(medulla and spinal cord) (fig 2, left panel). In
the search for the 3' end of FMR3, two ESTs
derived from the same cDNA clone (N66183
and N99175) were identified more proximal
(∼6 kb) to the FRAXE CpG island. A 541 bp
PCR probe just distal to the polyadenylation
signal observed in the EST N66183 was
designed and generated by RT-PCR on human
adult brain mRNA using standard techniques.9
The following oligonucleotide primers were
used: F10 5'-CTA TGC TGC TAT GCA
ACGACG-3' and R5 5'-ACACTTAGCACT
GCT GAT GTC ACC-3'. Northern blot
hybridisation showed the same size transcript
(∼ 3.8 kb) as detected with the EST AI470948
clone insert (fig 2, right panel). However, in
addition to the ∼3.8 kb transcript one larger
and two smaller sized transcripts were detected
(arrows, fig 2, right panel). It is not yet clear
whether these transcripts are the result of an
alternative splicing of the FMR3 gene or alter-
native transcription start sites.
In searching for additional introns and exons
within the FMR3 gene, EST AI470948 was
fully sequenced and the region between ESTs
AI470948 and N66183 was subdivided into
500-900 bp regions and amplified from oligo
dT primed human adult brain cDNA. No
additional exons were detected, which would
indicate that the FMR3 gene is composed of
only two exons. Careful analysis of the region
of the FMR3 transcript did not show any pro-
tein coding open reading frame (ORF) within
the FMR3 transcript, although smaller ORFs
(up to 51 amino acids) were present. Thus,
based on currently available information, we
can only speculate that the FMR3 is a protein
coding gene.
To investigate whether this gene is subject to
transcriptional repression in subjects with
FRAXE CCG full mutations, fibroblast RNA
from seven FRAXE full mutations, one
FRAXE premutation, two known FMR2 dele-
tion patients, and controls was analysed by
RT-PCR.7 The result of this experiment is
shown in fig 3. As in the FMR2 gene (fig 3,
middle panel) the newly identified gene FMR3
is transcriptionally silenced in FRAXE full
mutations (fig 3, upper panel). FMR3 tran-
scripts were detected in a FRAXE premutation
and in controls. FMR3 transcription was also
detected in two FMR2 deletion patients. These
results show that absence of FMR3 expression
might also contribute to the FRAXE MR phe-
notype.
The mental retardation in FRAXE is mild to
borderline (50<IQ<85) without any dysmor-
phic features. There are at present six docu-
mented cases of FRAXE full mutations with a
clinically normal phenotype,4 although the
level of FMR2 expression was tested in only
two of them.7 Identification of yet another
gene, FMR3, associated with the FRAXE frag-
ile site is intriguing, especially the extent of any
contribution this gene might have to FRAXE
MR. Currently, there is only one FMR2 muta-
tion (deletion of exons 2 and 3) which aVects
only the FMR2 gene (where a truncated
protein would be produced) and not FMR3.
All other FRAXE full mutations so far tested
have had both FMR2 and FMR3 transcripts
Figure 2 Northern blot analysis of FMR3. FMR3 probes (5' and 3') were hybridised to human brain II Northern blot
(Clontech). FMR3 transcript of ∼3.8 kb was detected in medulla and spinal cord. Additionally, two smaller and one larger
transcript (of slightly lower abundance) were detected with the 3' end FMR3 probe (right panel, indicated by arrows). A 5'
end probe 1.2 kb insert of EST AI470948 was used. The 3' end probe was derived by RT PCR based on the sequence of
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absent. Thus, it is diYcult to estimate the
extent of the contribution of FMR3 to the
FRAXE MR clinical phenotype and to estab-
lish whether the aVected phenotype is the
result of more than one gene.
Several deletions of the FMR3/FMR2 5' end
region have been described. These were identi-
fied either from a FRAXA full mutation male10
or females with premature ovarian failure
(POF,11 fig 1A). While the contribution of the
FMR2/FMR3 genes to the FRAXA phenotype
of the deletion patient of Brown et al10 is
diYcult to assess (because of the severity of the
FRAXA phenotype), the four deletions re-
ported by Murray et al11 may help to determine
the relative contributions of the FMR2/FMR3
genes to POF, as these aVect transcription
starts of either the FMR3 or the FMR2 gene.
The identification of a second gene associ-
ated with the FRAXE (CCG)n repeat is novel
and may help to resolve unanswered questions
about FRAXE MR and the aetiology of POF.
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Figure 3 RT-PCR analysis of FMR3 and FMR2 genes in fibroblasts of FRAXE full
mutations. FMR3 expression was not detected in subjects with a full mutation at FRAXE.
For FMR3, initially 20 cycles were performed using primers F1, 5'-CGG AGC CTG GAC
AGC TAG AAG C-3' and R1, 5'-AGT AGC TGA TGC TCA GTG AGC-3' followed by
30 cycles with primers F2, 5' - GCT AGA AGC CGC GAC ATG GAG C -3' and R2, 5'
-TGT TTG AGG AGA GTG GCT AGG AAG -3'. For FMR2, primers 14 and 62 were
used.9 Esterase D (ESD) was used as a control.9 gDNA denotes genomic DNA and M
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